Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.95 USD

10.95
442,291

-0.24 (-2.15%)

Updated Sep 11, 2024 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Moving Average Crossover Alert: Dynavax (DVAX)

Dynavax Technologies (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Dynavax Technologies (DVAX) Reports Q3 Loss, Tops Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25.00% and 21.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Dynavax Technologies (DVAX) closed at $3.87, marking a -1.53% move from the previous day.

Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know

Dynavax Technologies (DVAX) closed the most recent trading day at $4.17, moving +0.72% from the previous trading session.

Dynavax Technologies (DVAX) Gains As Market Dips: What You Should Know

Dynavax Technologies (DVAX) closed the most recent trading day at $4.22, moving +0.24% from the previous trading session.

Implied Volatility Surging for Dynavax (DVAX) Stock Options

Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.

Implied Volatility Surging for Dynavax (DVAX) Stock Options

Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.

Ritujay Ghosh headshot

5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

Millions are pinning their hopes on a handful of drugmakers, which are into the final phases of their vaccine trial.

Dynavax Technologies (DVAX) Reports Q2 Loss, Misses Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -12.50% and -53.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Ritujay Ghosh headshot

Pharma Stocks in Focus on Late-Stage Coronavirus Vaccine Trials

Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.

Will Dynavax Technologies (DVAX) Report Negative Q2 Earnings? What You Should Know

Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: Amgen Reports Q2, GILD's CAR T Therapy Gets Approval & More

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

Ritujay Ghosh headshot

Coronavirus Vaccine Development Puts These Stocks in Focus

Moderna and Pfizer launches two 30,000-subject trials of COVID-19 vaccines that could clear the way for regulatory approval and widespread use by the end of this year.

Is a Beat in Store for Dynavax (DVAX) This Earnings Season?

Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.

Dynavax Technologies (DVAX) Stock Moves -0.3%: What You Should Know

Dynavax Technologies (DVAX) closed the most recent trading day at $10.12, moving -0.3% from the previous trading session.

Dynavax Signs a Pact to Develop Universal Influenza Vaccine

Dynavax (DVAX) inks a deal with Mount Sinai to develop a universal influenza vaccine candidate using its CpG 1018 adjuvant. The development is funded under a contract win from NIAID.

Dynavax Technologies (DVAX) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Dynavax Technologies (DVAX) closed at $8.51, marking a -1.73% move from the previous day.

Do Options Traders Know Something About Dynavax Technologies (DVAX) Stock We Don't?

Investors need to pay close attention to Dynavax Technologies (DVAX) stock based on the movements in the options market lately.

Ritujay Ghosh headshot

4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine

The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

Is (DVAX) Outperforming Other Medical Stocks This Year?

Moving Average Crossover Alert: Dynavax Technologies

Dynavax Technologies Corporation (DVAX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Dynavax's Partner Doses First Patient in Coronavirus Study

Dynavax's (DVAX) China-based partner initiates dosing in a phase I study evaluating a COVID-19 vaccine using the company's proprietary CpG 1018 adjuvant. Preliminary data are expected in August.

Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine

Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.

Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.